SUMMARY Eighty two children with acute lymphoblastic leukaemia presenting at this hospital received one or two modules of intensive chemotherapy to consolidate remission. Modules were given after four and roughly 19 weeks on treatment. Each included two doses of daunorubicin (45 mg/m2/day), cytosine arabinoside (100 mg/M2 twice daily x 5), etoposide (100 mg/m2/dayx5), and 6-thioguanine (80 mglm2/day x 5). A total of 132 courses were given. This study included all new patients except girls aged 1-14 years with presenting leucocyte count < 20x 109/l. Twenty patients with recurrent disease were also included.
The first 32 patients were given cytosine as a 24 hour infusion, but combined with the other agents this was associated with severe intestinal toxicity, which necessitated a change to a less toxic 12 hourly bolus regimen. The complications of the module are reviewed in terms of myelosuppression, enterotoxicity, infection, and other clinical problems encountered. All patients became profoundly neutropenic and thrombocytopenic. The latter was significantly more severe after cytosine infusion. Overall, 64% received platelet transfusions and 85% were re-admitted with fevers requiring intravenous antibiotics for between four and 56 days. Gastrointestinal toxicity with the modified module occurred in 38% of patients and was severe in 13%.
This intensification module has been adopted by the Medical Research Council Working Party on Childhood Leukaemia for use in a multicentre study (UKALL X) and the details of the problems encountered in the pilot study may be of value to other centres now using this protocol.
Over 90% of children with acute lymphoblastic leukaemia will enter remission after treatment with vincristine, prednisolone, and asparaginase, but a large number will subsequently relapse. In 'good risk' girls with common acute lymphoblastic leukaemia and low presenting white blood cell count (WBC), long term survival of around 80% may be achieved.
For others, however, the outlook is less optimistic, and for boys with a high presenting WBC, long term survival is generally less than 40%
As in other childhood cancer the increased long term survival has accentuated the awareness of the long term side effects of chemoradiotherapy. In the past few years a number of centres have studied the effect of additional agents given during the induction period.3 Few have shown any clear benefit,4 5 but many such regimens have been insufficiently intensive. Although not assessed prospectively, however, it seems likely that the multiagent intensification by the BFM group has improved outcome.6
In the current Medical Research Council national trial (UKALL X) the possible advantages of similarly intensive consolidation therapy are being assessed in a randomised manner. A pilot study of a five day module, which comprised daunorubicin, cytosine arabinoside, Figure 1 and the consolidation module DATE in Figure 2 . The first 25 patients were given cytosine as a continuous infusion over the five days, and all subsequent patients were given 12 hourly intravenous bolus injections.
The elective times for early and late consolidation were at four and 19 weeks, respectively (Fig. 1) Seven patients were given the early module only. late cranial irradiation as a result of complications associated with the early module; in one irradiation was delayed for a short period until the child was 2 years old and then followed by the late module; in eight the delay was due to severe neutropenia related to intolerance of maintenance therapy started at the time of cranial irradiation; in one the delay was due to herpes zoster infection; and in two patients (both with low presenting WBC) the late module was delayed for one to two weeks for family reasons.
In all cases the blood count had recovered from previous treatment at the time of the module, with neutrophil count >1x109/l, platelets >100X109/l, and haemoglobin >8 g/dl. The patient's general condition, particularly in relation to nutrition and infection, was taken into account in deciding about the module timing and was balanced against prognostic factors such as age, sex, presenting WBC, and extramedullary disease at diagnosis. Follow up and management of patients. Blood counts and blood product support Weekly blood counts were increased to dailyV once the platelet count had fallen to below 50x 10 /1, and platelet transfusions were given at below 20x 109/l or ment with antibiotics.
Management of infections
In view of the profound myelosuppression a high incidence of infectious complications were anticipated and at the start of the study all patients remained in hospital until the neutrophil count began to recover. Subsequently, all were allowed home after completion of chemotherapy, except infants in whom the signs of infection may be subtle, or where there was any doubt about parental ability to appreciate the need for early re-admission. Parents were advised to take the child's temperature if she or he appeared warm or in any way unwell. A temperature above 38°C was regarded as an indication to contact the hospital and usually led to re-admission. Oral decontamination of the bowel was not attempted, nor was protective isolation used.
The investigations carried out in the febrile neutropenic patients were as previously described,7 with the addition of blood cultures in Sabauroud's medium, serial fungal serology, and viral culture and serology as clinically indicated. Stool samples were routinely screened twice weekly for conventional intestinal pathogens, and the identity and antibiogram of the aerobic Gram negative bowel flora were also determined. The results of the latter investigations were used to determine whether initial treatment with antibiotics should be the first or second line antibiotic policy of the unit. In the If the temperature settled promptly and no causative agent was found treatment with antibiotics was stopped when the child had been afebrile for 48 hours, irrespective of the blood count. Documented bacteraemia was followed by a 10 day course of appropriate treatment with antibiotics.
In patients in whom fever failed to settle within five days of treatment with antibiotics, appropriate for cover of the aerobic Gram negative bowel flora, intravenous amphotericin was used. Early treatment was influenced by the presence of candida in gut, mouth, or skin and was reviewed in the light of clinical response and serial candida serology estimated every three to five days. The duration of treatment with amphotericin was based on the documentation of presence or absence of systemic candida infection, which was indicated by a rise in antigen or antibody, or both. Where systemic sepsis was documented a course of six weeks' treatment was given. Where three serial estimations of antigen and antibody failed to reveal evidence of systemic disease treatment was stopped after two to three weeks or on recovery of the neutrophil count.
Enterotoxicity
As with suspected infection a low threshold for re-admission was maintained and parents were advised to contact the hospital in the event of any intestinal symptoms. If diarrhoea developed the child was re-admitted for observation and early intravenous fluids given if symptoms did not settle. With severe enterotoxicity, parenteral nutrition was begun early, particularly in patients whose nutritional state was already suboptimal.
Results
As the amount of previous treatment might have influenced toxicity patients have been subdivided with regard to the timing of the module-that is, late module only, early module, or second module given to the same patient (repeat late module). The method of administration of cytosine is also considered and whether the patient was in first or subsequent remission. The times given refer to the number of days after starting the module. Statistical differences between groups were assessed using the X2 test. (Table 3 ). The neutrophil count fell to below 0-5 x I09/1 in all patients and to undetectable numbers in most. The onset of neutropenia ranged from day 7-12 in new cases and 1-12 in patients with recurrent disease and the duration of neutropenia from 6-20 and 7-40 days, respectively. Severe thrombocytopenia occurred in many patients, the timing of onset ranging from day 5-17. Sixty four per cent of patients required platelet transfusions, and platelet requirements were higher in cases who had received cytosine as an infusion rather than as a bolus (88% v 56%, p<0001). Bruising and petechiae were not uncommon, but with the exception of intestinal haemorrhage in patients with severe enterotoxicity there were no serious bleeding problems. In three patients myelosuppression was particularly severe, lasting over three weeks. Two of these had recurrent disease and had been heavily pretreated. The other, a new case, developed severe enterotoxicity and septicaemia and, despite initial partial recovery of blood count, remained profoundly neutropenic and thrombocytopenic and developed candida septicaemia. After eight weeks his count had completely recovered and he proceeded into maintenance therapy.
Enterotoxicity. This was graded according to severity ( Table 4 ). The timing of onset of symptoms ranged from day 5-16 and their duration from 1-35 days (Table 4) .
Characteristically, patients remained well during the administration of the module apart from some nausea and vomiting associated with daunorubicin. Cytosine was in general well tolerated with no conjunctival, skin, or neurological reactions.
The Repeat late I Intestinal toxicity grading: 1 Occasional crampy pain; 11 Cramps and two to three loose motions each day, oral replacement; 111 Severe diarrhoea requiring intravenous fluids; IV Florid enterocolitis, usually requiring parentral feeding. Cytosine arabinoside administration: I= infusion, B=bolus. DATE comprised daunorubicin, cytosinc arabinoside, 6-thioguanine, and etoposide.
group.bmj.com on April 5, 2017 -Published by http://adc.bmj.com/ Downloaded from blood cultures yielded positive results, received granulocyte transfusions. Six patients, four of whom had been given cytosine by infusion, received amphotericin because of unremittent fever, but in one case this was for severe candida oesophagitis. The duration of antifungal treatment ranged from five to 56 days (median 14 days). One fifth of the modules were followed by the use of intravenous metronidazole, mostly in the earlier patients in whom intestinal toxicity was more severe. Acyclovir was given in seven cases: in two as empirical treatment in unexplained encephalopathy but without firm supportive evidence for herpes infection, in one for severe facial herpes zoster, and in four for herpes simplex stomatitis.
Mortality. Two patients died after the unmodified module (infusion of cytosine) and one after the modified (bolus cytosine), an overall mortality of 3-6%. Both of the patients who died after the unmodified module had recurrent disease.
One girl, aged 13 years, with isolated central nervous system relapse, developed a fever on day 9, which persisted in hospital despite treatment with antibiotics. She died on day 11 with a fulminant E. coli septicaemia and intramesenteric haemorrhage.
A 4 year old girl, who had relapsed in the bone marrow on maintenance therapy, collapsed and died within a few hours of admission to her local hospital with a fever and mild diarrhoea that developed 48 hours after completing treatment. Although blood cultures yielded negative results, it was assumed this death was due to septicaemia. Postmortem examination revealed no specific cause and in particular no evidence of cardiomyopathy (she had received 315 mg/M2 daunorubicin).
The child who died in first remission was a 2 year old girl with a presenting WBC of 231 x 109/l. She had a very stormy induction period, developing septicaemia and enterotoxicity, the latter probably due to the initial treatment with daunorubicin. Because of these problems the early module was delayed until week 5. Despite this, she developed diarrhoea on day three of the module and died on day 15 with fulminant Pseudomonas aeruginosa septicaemia.
Discussion
As might be expected with any intensive combination chemotherapy regimen the morbidity associated with the DATE module was high. With the modified form, 85% of patients required readmission to hospital because of fever, and 13% developed severe enterotoxicity. 
